Xenon to Report Q1 2026 Financial Results on May 7, 2026

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq: XENE) will report Q1 2026 financial results and provide a business update after U.S. markets close on May 7, 2026 at 4:30pm ET.

A live webcast will be available via the company website; dial-in details and conference ID 7898598 are provided for callers. Xenon’s lead molecule, azetukalner, is in Phase 3 for epilepsy, major depressive disorder, and bipolar depression. The company also has Phase 1 KV7 and NaV1.7 programs targeting pain and maintains offices in Vancouver and Boston.

Positive

• Lead molecule azetukalner in Phase 3 for epilepsy, MDD and BPD
• Early-stage KV7 and NaV1.7 programs in Phase 1 for pain

Negative

• None.

News Market Reaction – XENE

+0.16%

+0.16% Session close to close

In the May 1 session, XENE gained 0.16%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets expectations for Xenon’s Q1 2026 earnings release and business update on May ...

Analysis

This announcement sets expectations for Xenon’s Q1 2026 earnings release and business update on May 7, 2026 at 4:30pm ET. Context includes recent Phase 3 azetukalner data and substantial equity raises in March, which shaped the company’s capital position ahead of the call. Investors may focus on how management frames cash usage, development timelines for Phase 3 and Phase 1 programs, and any updates to regulatory or commercial planning for azetukalner.

Key Figures

Earnings date: May 7, 2026 Earnings call time: 4:30pm ET Conference ID: 7898598 +5 more

8 metrics

Earnings date May 7, 2026 Q1 2026 financial results release after U.S. market close

Earnings call time 4:30pm ET Scheduled Q1 2026 webcast start time

Conference ID 7898598 ID for Q1 2026 results dial-in

Azetukalner phase Phase 3 Clinical trials in epilepsy, MDD and bipolar depression

Pipeline stage Phase 1 KV7 and NaV1.7 programs in development for pain

Current price $55.75 Price before Q1 2026 earnings date announcement

52-week range $28.19–$63.95 Positioned near upper end before earnings update

Market cap $5,269,933,084 Equity value prior to Q1 2026 results

Historical Context

5 past events · Latest: 2026-04-19 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
2026-04-19	Phase 3 data	Positive	-4.4%	Strong X-TOLE2 and 48-month azetukalner seizure-reduction data presented at AAN.
2026-04-15	Investor conferences	Neutral	-0.8%	Announcement of four Q2 2026 investor conference presentations and webcast access.
2026-04-07	Conference preview	Positive	+1.4%	Planned AAN presentations including late-breaking Phase 3 X-TOLE2 and long-term data.
2026-03-12	Equity offering close	Negative	-4.6%	Closing of upsized public offering raising about $747.5M in gross proceeds.
2026-03-10	Equity offering pricing	Negative	-2.6%	Pricing of upsized $650.0M public offering of shares and pre-funded warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive clinical and financing news often saw price declines, while offering announcements aligned with negative reactions.

Recent Company History

Over the last few months, Xenon has progressed both clinical and financing milestones. On Mar 10–12, 2026, it priced and closed large upsized public offerings raising about $650.0M and $747.5M, which coincided with share price declines. In April, the company highlighted and then presented Phase 3 X-TOLE2 and long-term azetukalner data at the 2026 AAN meeting, showing substantial seizure reductions but drawing a mixed price reaction. An April investor-conference schedule had only a modest negative move. Today’s earnings-date notice fits within this cadence of frequent, event-driven updates.

Key Terms

phase 3 clinical trials, phase 1 development, kv7 potassium channel opener, nav1.7

4 terms

phase 3 clinical trials medical

"azetukalner, is a novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy"

Phase 3 clinical trials are large, late-stage studies that test a drug or medical treatment in hundreds to thousands of patients to confirm it is safe and effective and to compare it with existing options. Investors care because positive results are a key step toward regulatory approval and commercial sales, reducing uncertainty much like a full dress rehearsal before a product launch; negative results can sharply reduce a program’s value.

phase 1 development medical

"including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain"

Phase 1 development is the first stage of testing a new drug or medical therapy in humans, focused on safety, how the body handles the treatment, and identifying a safe dose range. For investors it is an early milestone that reduces uncertainty—think of it like a prototype’s first test drive: passing it doesn’t prove long-term success but failing it can halt the program and materially affect a company’s value.

kv7 potassium channel opener medical

"azetukalner, is a novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials"

A Kv7 potassium channel opener is a drug that helps certain cellular ‘gates’ called Kv7 channels stay open so potassium can flow out of cells, calming electrical activity in nerves and muscle. For investors, these compounds matter because they can form the basis of treatments for conditions driven by excessive electrical firing—like some seizures, pain, or heart rhythm disorders—so successful candidates can create new medical markets or reduce risks in drug pipelines.

nav1.7 medical

"including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain"

NAV1.7 is a specific protein in nerve cells that helps transmit pain signals to the brain; think of it as a gatekeeper that opens and closes to let electrical messages through. Investors watch drugs that block or modify NAV1.7 because successful therapies could relieve chronic pain without opioids, creating large market opportunities, while clinical setbacks or safety issues can sharply affect a company's valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its first quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, May 7, 2026.

Company Presentation Details:

Date:	Thursday, May 7, 2026
Time:	4:30pm ET (1:30pm PT)
Webcast:	Pre-register here
Dial-In:	(800) 715-9871 toll-free or (646) 307-1963 for international callers
Conference ID:	7898598

A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event. The above-mentioned dates and times are subject to change.

About Xenon Pharmaceuticals Inc. 

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective K_V7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K_V7 and Na_V1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X. 

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner. 

Contacts: 

For Investors:  
Tucker Kelly  
Chief Financial Officer  
investors@xenon-pharma.com  

For Media:  
Colleen Alabiso  
Senior Vice President, Corporate Affairs  
media@xenon-pharma.com  

FAQ

When will Xenon (XENE) report Q1 2026 results and host its investor webcast?

Xenon will report Q1 2026 results and present after market close on May 7, 2026 at 4:30pm ET. According to Xenon, a live webcast and replay will be available on the company investor website with dial-in conference access.

How can investors access the Xenon (XENE) May 7, 2026 presentation webcast and dial-in?

Investors can access the live webcast via the company investor website and pre-register online. According to Xenon, dial-in numbers include a U.S. toll-free line and international number with conference ID 7898598.

What is the clinical status of Xenon’s lead candidate azetukalner (XENE)?

Azetukalner is in Phase 3 clinical trials for epilepsy, major depressive disorder, and bipolar depression. According to Xenon, azetukalner is a selective KV7 potassium channel opener being advanced toward potential regulatory milestones.

Does Xenon (XENE) have programs targeting pain, and what stages are they in?

Yes. Xenon is advancing KV7 and NaV1.7 channel modulators targeting pain, currently in Phase 1 development. According to Xenon, these are early-stage programs building its pipeline beyond azetukalner.

Where are Xenon (XENE) offices located and how can investors contact the company?

Xenon has offices in Vancouver, British Columbia and Boston, Massachusetts. According to Xenon, investor and media contact emails are provided on the company website for questions and follow-up.